ClinicalTrials.gg
CompletedNCT03758365Updated Jan 9, 2020Results posted

Evaluation of the Vasoconstriction Properties of MC2-01 Cream

A Phase 1 interventional study of MC2-01 Cream and Clobetasol Propionate 0.05% Lotion in Vasoconstriction, sponsored by MC2 Therapeutics. Completed at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-09.

Sponsored by MC2 Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The objective of this trial is to compare the vasoconstriction potential

Read the detailed description

The objective of this trial is to compare the vasoconstriction potential (skin blanching effect) of MC2-01 cream with 5 comparators and MC2-01 vehicle using the human skin blanching test (McKenzie-Stoughton's test).

02

Conditions studied

  • Vasoconstriction
03

In context

Lead sponsor

MC2 Therapeutics is the lead sponsor of 9 studies on the registry; none are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 years to 50 years old having signed and dated an ,
  2. Non-smoker subjects,
  3. Subjects demonstrating adequate vasoconstriction to Diprolene® cream within 15 days prior to dosing (unoccluded application of Diprolene® cream for 4-6 hours must show a visual score of skin blanching of at least one unit (visual scale (0-4)),
  4. Subjects without signs of skin irritation/disease/disorders/symptoms or blemishes on test sites (e.g. erythema, dryness, roughness, scaling, scars, moles, sunburn),
  5. Female subjects of non- defined as surgically sterile or (at least one year post cessation of menses),
  6. Female subjects of childbearing potential who have been, in the opinion of the Investigator, using an approved method of (e.g. oral contraception pill or patch, intra-uterine devices, contraceptive implants or vaginal rings, condoms, bilateral tubal ligation) at trial entry and agree to continue until the end of the last trial visit,
  7. Female subjects of childbearing potential must have a negative urine pregnancy test at screening visit and at Day 1 to continue,
  8. Subjects willing and able to follow all the trial procedures and complete the whole trial,
  9. Subjects affiliated to a social security system.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are breastfeeding,
  2. Use of topical on the test areas (forearms) within 4 weeks prior to the screening phase,
  3. Use of systemic drugs which may interfere with the blanching reaction including, but not limited to, corticosteroids and other vasoactive drugs (nitrates derivatives, antihypertensive, phenylpropanolamine, diphenhydramine, pseudo-ephedrine, antihistamines, non-steroidal anti-inflammatory drug and aspirin/acetylsalicylic acid), within two weeks prior to screening visit,
  4. Use of any other medication would interfere with the trial results, in particular topical drugs applied on the test area within two weeks prior to screening visit,
  5. Subjects having a caffeine (i.e. coffee, cola, soft-drinks containing caffeine) intake greater than 500mg per day (1 cup of coffee contains approximately 85mg of caffeine) within one day prior to screening visit and until the end of the last visit of the test phase,
  6. Subjects with a history of drug or alcohol abuse/addiction.
  7. Abnormal pigmentation of the skin or skin type, that could, in any way, confound interpretation of the trail results (skin type V to VI on the Fitzpatrick scale),
  8. Subjects with obvious difference in skin color between arms,
  9. Subjects with any of the following conditions present on the test areas: viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, atrophic skin, and striae atrophicae, fragility of skin veins, ichthyosis and ulcers,
  10. Any current systemic or cutaneous disease that could in any way confound interpretation of the trial results (e.g. atopic dermatitis, contact eczema, or psoriasis),
  11. Known or suspected to any component(s) of Medical Product (IMP),
  12. Subjects with current participation in any other interventional clinical, based on interview of the subject,
  13. Subjects who have received treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the last 4 weeks prior to screening phase,
  14. Previously enrolled in this clinical trial,
  15. Subjects who do not accept to avoid strenuous physical activity nor alcohol intake during the study.
  16. In the opinion of the (sub)investigator, subjects who are unlikely to comply with the Clinical Trial Protocol (e.g. alcoholism, drug dependency or psychotic state),
  17. Subjects in close affiliation with the trial personnel (e.g. immediate family member or subordinate), subjects being a member of the clinical trial personnel, or being an employee of the sponsor or a Contract Research Organisation (CRO involved in the trial,
  18. Subjects impossible to contact in case of emergency,
  19. Subjects who are in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization,
  20. Subjects under guardianship, hospitalized in a public or private institution, for a reason other than the research or subject deprived of freedom.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    MC2-01 Cream

    Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream

    Drug: MC2-01 Cream

  • Active comparator
    Clobetasol propionate 0.05% lotion

    Single application of Clobetasol propionate 0.05%,

    Drug: Clobetasol Propionate 0.05% Lotion

  • Active comparator
    Betamethasone dipropionate 0.05% cream

    Single application of Betamethasone dipropionate 0.05%,

    Drug: Betamethasone Dipropionate 0.05% Cream

  • Active comparator
    Triamcinolone acetonide 0.1% cream

    Single application of Triamcinolone acetonide 0.1%,

    Drug: Triamcinolone Acetonide 0.1% Cream

  • Active comparator
    Hydrocortisone Butyrate 0.1% cream

    Single application of Hydrocortisone Butyrate 0.1% Cream

    Drug: Hydrocortisone Butyrate 0.1% Cream

  • Active comparator
    Desonide 0.05% cream

    Single application of Desonide 0.05%

    Drug: Desonide 0.05% Cream

  • Placebo comparator
    Vehicle cream

    Single application of Vehicle

    Drug: Vehicle

Interventions

  • DrugMC2-01 Cream

    Drug pages: Calcipotriene · Betamethasone dipropionate

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

    Also known as: Calcipotriol + Betamethasone dipropionate cream

  • Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

    Also known as: Clobex

  • Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

    Also known as: Betamethasone Dipropionate

  • Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

    Also known as: Triamcinolone acetonide

  • Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

    Also known as: Locoid® cream

  • Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

    Also known as: Desowen® cream

  • DrugVehicle

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

    Also known as: Vehicle cream

06

What researchers measure

Primary outcomes

  1. Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle

    Blanching of the skin will be assessed individually by two trained observers blinded to treatment. The observers will score the blanching of the skin from 0-4 (0 = No change in color skin; 1 = Slight (barely visible) blanching; 3 = Obvious blanching; 4 = Blanching judged to be maximal). The results is presented as Mean ± SD.

    Time frame: Day 2

  2. Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle

    The local tolerability of the creams will be assesed using a predefined scale: 0 = No reaction; 0.5 = Only slight erythema; 1 = Only erythema; 2 = Erythema with papules or oedema; 3 = Erythema, oedema with papules, oedema with vesicle; 4 = Blisters

    Time frame: Day 2

07

Results

Posted Jan 9, 2020

Participant flow

First Subject First Visit: 07-Nov-2018. Last Subject Last Visit: 23-Nov-2018

Participant flow — Overall Study
MilestoneMC2-01 Cream + Comparators
Started36
Mc2-01 cream36
Clobetasol propionate 0.05% lotion36
Betamethasone dipropionate 0.05% cream36
Triamcinolone acetonide 0,1% cream36
Hydrocortisone butyrate 0.1% cream36
Desonide 0.05% cream36
Vehicle cream36
Completed36
Not completed0

Outcome measures

PrimaryComparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle

Blanching of the skin will be assessed individually by two trained observers blinded to treatment. The observers will score the blanching of the skin from 0-4 (0 = No change in color skin; 1 = Slight (barely visible) blanching; 3 = Obvious blanching; 4 = Blanching judged to be maximal). The results is presented as Mean ± SD.

Time frame:
Day 2
Reported as:
Mean · score on a scale
Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle
score on a scaleMC2-01 Cream + Comparators
MC2-01 Cream1.66 ± 0.57
Clobetasol Propionate 0.05% Lotion3.05 ± 0.65
Betamethasone Dipropionate 0.05% Cream2.45 ± 0.61
Triamcinolone Acetonide 0.1% Cream1.92 ± 0.89
Hydrocortisone Butyrate 0.1% Cream2.06 ± 0.70
Desonide 0.05% Cream2.11 ± 0.85
Vehicle Cream0.14 ± 0.25
PrimaryCompare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle

The local tolerability of the creams will be assesed using a predefined scale: 0 = No reaction; 0.5 = Only slight erythema; 1 = Only erythema; 2 = Erythema with papules or oedema; 3 = Erythema, oedema with papules, oedema with vesicle; 4 = Blisters

Time frame:
Day 2
Reported as:
Count of participants · Participants
Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle
ParticipantsMC2-01 Cream + Comparators
MC2-01 Cream — No reaction36
MC2-01 Cream — Only Slight reaction0
MC2-01 Cream — Only erythema0
MC2-01 Cream — Erythema with papules or oedema0
MC2-01 Cream — Erythema, oedema with papules, oedema with vesicle0
MC2-01 Cream — Blisters0
Clobetasol Propionate 0.05% Lotion — No reaction36
Clobetasol Propionate 0.05% Lotion — Only Slight reaction0
Clobetasol Propionate 0.05% Lotion — Only erythema0
Clobetasol Propionate 0.05% Lotion — Erythema with papules or oedema0
Clobetasol Propionate 0.05% Lotion — Erythema, oedema with papules, oedema with vesicle0
Clobetasol Propionate 0.05% Lotion — Blisters0
Betamethasone Dipropionate 0.05% Cream — No reaction36
Betamethasone Dipropionate 0.05% Cream — Only Slight reaction0
Betamethasone Dipropionate 0.05% Cream — Only erythema0
Betamethasone Dipropionate 0.05% Cream — Erythema with papules or oedema0
Betamethasone Dipropionate 0.05% Cream — Erythema, oedema with papules, oedema with vesicle0
Betamethasone Dipropionate 0.05% Cream — Blisters0
Triamcinolone Acetonide 0.1% Cream — No reaction36
Triamcinolone Acetonide 0.1% Cream — Only Slight reaction0
Triamcinolone Acetonide 0.1% Cream — Only erythema0
Triamcinolone Acetonide 0.1% Cream — Erythema with papules or oedema0
Triamcinolone Acetonide 0.1% Cream — Erythema, oedema with papules, oedema with vesicle0
Triamcinolone Acetonide 0.1% Cream — Blisters0
Hydrocortisone Butyrate 0.1% Cream — No reaction36
Hydrocortisone Butyrate 0.1% Cream — Only Slight reaction0
Hydrocortisone Butyrate 0.1% Cream — Only erythema0
Hydrocortisone Butyrate 0.1% Cream — Erythema with papules or oedema0
Hydrocortisone Butyrate 0.1% Cream — Erythema, oedema with papules, oedema with vesicle0
Hydrocortisone Butyrate 0.1% Cream — Blisters0
Desonide 0.05% Cream — No reaction36
Desonide 0.05% Cream — Only Slight reaction0
Desonide 0.05% Cream — Only erythema0
Desonide 0.05% Cream — Erythema with papules or oedema0
Desonide 0.05% Cream — Erythema, oedema with papules, oedema with vesicle0
Desonide 0.05% Cream — Blisters0
Vehicle Cream — No reaction36
Vehicle Cream — Only Slight reaction0
Vehicle Cream — Only erythema0
Vehicle Cream — Erythema with papules or oedema0
Vehicle Cream — Erythema, oedema with papules, oedema with vesicle0
Vehicle Cream — Blisters0

Adverse events

Collected over AEs were collected/assessed from the time the informed consent form was signed at the screening visit, which could occur up to 14 days prior to the test period, during the 2 day's test period and until the follow-up visit, 15 days following the test period, had occurred. AEs assessed as reasonably possibly related to the trial medication had to be followed until they were resolved or until the medical condition of the subject was stable.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MC2-01 Cream0/36 (0%)0/36 (0%)0/36 (0%)
Clobetasol Propionate 0.05% Lotion0/36 (0%)0/36 (0%)0/36 (0%)
Betamethasone Dipropionate 0.05% Cream0/36 (0%)0/36 (0%)0/36 (0%)
Triamcinolone Acetonide 0.1% Cream0/36 (0%)0/36 (0%)0/36 (0%)
Hydrocortisone Butyrate 0.1% Cream0/36 (0%)0/36 (0%)0/36 (0%)
Desonide 0.05% Cream0/36 (0%)0/36 (0%)0/36 (0%)
Vehicle Cream0/36 (0%)0/36 (0%)0/36 (0%)

Baseline characteristics

All patients received all 7 types of treatments.

Age, Continuous
Age, Continuous(years)MC2-01 Cream + Comparators
Mean34.36 ± 6.57
Sex: Female, Male
Sex: Female, Male(Participants)MC2-01 Cream + Comparators
Female28
Male8
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)MC2-01 Cream + Comparators
Region of Enrollment
Region of Enrollment(participants)MC2-01 Cream + Comparators
France36
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)MC2-01 Cream + Comparators
I0
II9
III24
IV3
V0
08

Study locations

1 site
  • CPCAD
    Nice, 06200, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Single site study

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Nov 2018, 0 months.

Results were first posted in Jan 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2018
First posted
Nov 29, 2018
StartActual
Nov 5, 2018
Primary completionActual
Nov 23, 2018
CompletionActual
Nov 23, 2018
Results first posted
Jan 9, 2020
Last update
Jan 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03758365
Lead sponsor
MC2 Therapeutics
Responsible party
Sponsor
First posted
Nov 29, 2018
Start date
Nov 5, 2018
Primary completion
Nov 23, 2018
Completion
Nov 23, 2018
Results posted
Jan 9, 2020
Last update
Jan 9, 2020

Study contacts

Catherine QUEILLE-ROUSSEL, MD
principal investigator · CPCAD, Centre de Pharmacologie Clinique Appliquée à la Dermatologie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate

Start the discussion